Sustained remission of severe multicentric castleman disease following multiagent chemotherapy and tocilizumab maintenance

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Castleman disease is a rare lymphoproliferative disorder, which presents in a unicentric or multicentric fashion. Multicentric Castleman disease (MCD) is associated with significant systemic symptoms, in part related to the underlying role of interleukin-6 in disease pathogenesis. Treatment for MCD has not been well established and prognosis has historically been poor. We present a case of severe MCD in a pediatric patient who has shown sustained remission following multi-agent chemotherapy and targeted maintenance therapy with the interleukin-6 receptor inhibitor, tocilizumab. This represents the first case report of sustained remission of MCD in a pediatric patient following discontinuation of tocilizumab therapy.

Original languageEnglish (US)
Pages (from-to)737-739
Number of pages3
JournalPediatric Blood and Cancer
Volume61
Issue number4
DOIs
StatePublished - Apr 1 2014

Fingerprint

Maintenance
Drug Therapy
Pediatrics
Giant Lymph Node Hyperplasia
Interleukin-6 Receptors
Lymphoproliferative Disorders
Interleukin-6
Therapeutics
tocilizumab
Multi-centric Castleman's Disease

Keywords

  • Anakinra
  • CHOP
  • Multicentric Castleman disease
  • Tocilizumab

Cite this

@article{26808b8b1cfc4b1d8157b1654aa147d4,
title = "Sustained remission of severe multicentric castleman disease following multiagent chemotherapy and tocilizumab maintenance",
abstract = "Castleman disease is a rare lymphoproliferative disorder, which presents in a unicentric or multicentric fashion. Multicentric Castleman disease (MCD) is associated with significant systemic symptoms, in part related to the underlying role of interleukin-6 in disease pathogenesis. Treatment for MCD has not been well established and prognosis has historically been poor. We present a case of severe MCD in a pediatric patient who has shown sustained remission following multi-agent chemotherapy and targeted maintenance therapy with the interleukin-6 receptor inhibitor, tocilizumab. This represents the first case report of sustained remission of MCD in a pediatric patient following discontinuation of tocilizumab therapy.",
keywords = "Anakinra, CHOP, Multicentric Castleman disease, Tocilizumab",
author = "Turcotte, {Lucie M} and Correll, {Colleen K} and Reed, {Robyn C} and Moertel, {Christopher L}",
year = "2014",
month = "4",
day = "1",
doi = "10.1002/pbc.24761",
language = "English (US)",
volume = "61",
pages = "737--739",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "4",

}

TY - JOUR

T1 - Sustained remission of severe multicentric castleman disease following multiagent chemotherapy and tocilizumab maintenance

AU - Turcotte, Lucie M

AU - Correll, Colleen K

AU - Reed, Robyn C

AU - Moertel, Christopher L

PY - 2014/4/1

Y1 - 2014/4/1

N2 - Castleman disease is a rare lymphoproliferative disorder, which presents in a unicentric or multicentric fashion. Multicentric Castleman disease (MCD) is associated with significant systemic symptoms, in part related to the underlying role of interleukin-6 in disease pathogenesis. Treatment for MCD has not been well established and prognosis has historically been poor. We present a case of severe MCD in a pediatric patient who has shown sustained remission following multi-agent chemotherapy and targeted maintenance therapy with the interleukin-6 receptor inhibitor, tocilizumab. This represents the first case report of sustained remission of MCD in a pediatric patient following discontinuation of tocilizumab therapy.

AB - Castleman disease is a rare lymphoproliferative disorder, which presents in a unicentric or multicentric fashion. Multicentric Castleman disease (MCD) is associated with significant systemic symptoms, in part related to the underlying role of interleukin-6 in disease pathogenesis. Treatment for MCD has not been well established and prognosis has historically been poor. We present a case of severe MCD in a pediatric patient who has shown sustained remission following multi-agent chemotherapy and targeted maintenance therapy with the interleukin-6 receptor inhibitor, tocilizumab. This represents the first case report of sustained remission of MCD in a pediatric patient following discontinuation of tocilizumab therapy.

KW - Anakinra

KW - CHOP

KW - Multicentric Castleman disease

KW - Tocilizumab

UR - http://www.scopus.com/inward/record.url?scp=84893476036&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893476036&partnerID=8YFLogxK

U2 - 10.1002/pbc.24761

DO - 10.1002/pbc.24761

M3 - Article

VL - 61

SP - 737

EP - 739

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 4

ER -